Further study of CD8+ BTRM cells is required to understand their role in post-infectious cognitive outcomes and the degree to which miR-155 inhibition is a viable adjunct to antimicrobial therapy in treatment of neuroinvasive bacterial infection. The gene discussed is CD8A; the disease is bacterial infectious disease.